Kymera Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
285
- Stock Symbol
-
KYMR
- Share Price
-
$115.01
- (As of Friday Closing)
Kymera Therapeutics General Information
Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Contact Information
Website
www.kymeratx.comCorporate Office
- 500 North Beacon Street
- 4th Floor
- Watertown, MA 02472
- United States
Corporate Office
- 500 North Beacon Street
- 4th Floor
- Watertown, MA 02472
- United States
Kymera Therapeutics Stock Performance
As of 20-Nov-2026, Kymera Therapeutics’s stock price is $115.01. Its current market cap is $9.8B with 85.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $115.01 | $119.39 | $63.69 - $142.92 | $9.8B | 85.4M | 847K | -$3.63 |
Kymera Therapeutics Financials Summary
As of 30-Sep-2026, Kymera Therapeutics has a trailing 12-month revenue of $102M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,682,981 | 5,803,039 | 2,143,768 | 1,135,727 |
| Revenue | 102,235 | 39,211 | 47,072 | 78,592 |
| EBITDA | (396,783) | (341,086) | (254,262) | (161,965) |
| Net Income | (349,425) | (311,351) | (223,858) | (146,962) |
| Total Assets | 1,767,269 | 1,742,812 | 978,035 | 575,759 |
| Total Debt | 76,599 | 82,252 | 87,761 | 84,674 |
Kymera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kymera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kymera Therapeutics Comparisons
Industry
Financing
Details
Kymera Therapeutics Competitors (33)
One of Kymera Therapeutics’s 33 competitors is Foghorn Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Foghorn Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Cullgen | Formerly VC-backed | San Diego, CA | ||||
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Kymera Therapeutics Patents
Kymera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236697-A1 | Irf5 degraders and uses thereof | Pending | 08-May-2025 | ||
| WO-2026236688-A1 | Irf5 inhibitors and uses thereof | Pending | 08-May-2025 | ||
| WO-2026196156-A1 | Cyclin-dependent kinase 2 (cdk2) molecular glue degraders | Pending | 17-Mar-2025 | ||
| WO-2026188211-A1 | Stat6 degraders and uses thereof | Pending | 06-Mar-2025 | ||
| WO-2026188071-A1 | Stat6 degraders and uses thereof | Pending | 05-Mar-2025 | C07D471/04 |
Kymera Therapeutics Signals
Kymera Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.05 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Kymera Therapeutics FAQs
-
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2015.
-
Where is Kymera Therapeutics headquartered?
Kymera Therapeutics is headquartered in Watertown, MA.
-
What is the size of Kymera Therapeutics?
Kymera Therapeutics has 285 total employees.
-
What industry is Kymera Therapeutics in?
Kymera Therapeutics’s primary industry is Drug Discovery.
-
Is Kymera Therapeutics a private or public company?
Kymera Therapeutics is a Public company.
-
What is Kymera Therapeutics’s stock symbol?
The ticker symbol for Kymera Therapeutics is KYMR.
-
What is the current stock price of Kymera Therapeutics?
As of 20-Nov-2026 the stock price of Kymera Therapeutics is $115.01.
-
What is the current market cap of Kymera Therapeutics?
The current market capitalization of Kymera Therapeutics is $9.8B.
-
What is Kymera Therapeutics’s current revenue?
The trailing twelve month revenue for Kymera Therapeutics is $102M.
-
Who are Kymera Therapeutics’s competitors?
Foghorn Therapeutics, Nurix Therapeutics, Cullgen, Vividion Therapeutics, and Arvinas are some of the 33 competitors of Kymera Therapeutics.
-
What is Kymera Therapeutics’s annual earnings per share (EPS)?
Kymera Therapeutics’s EPS for 12 months was -$3.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process